RENAMIN W/O ELECTROLYTES
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RENAMIN W/O ELECTROLYTES (RENAMIN W/O ELECTROLYTES).
Renamin w/o Electrolytes is a parenteral nutrition solution providing amino acids for protein synthesis and tissue repair in patients unable to tolerate oral or enteral nutrition. It does not contain electrolytes or dextrose.
| Metabolism | Amino acids are metabolized via transamination, deamination, and urea cycle; primarily hepatic. |
| Excretion | Renin is not excreted; it is an endogenous enzyme that acts locally. Exogenous renin would be cleared via hepatic metabolism and renal excretion as peptides. No specific % data available. |
| Half-life | Endogenous renin has a plasma half-life of approximately 15-30 minutes. Clinical context: short half-life allows rapid changes in angiotensin II generation. |
| Protein binding | Renin binds to renin-binding protein (RnBP) and prorenin receptor; plasma protein binding is not quantified as a %. |
| Volume of Distribution | Renin distribution volume is approximately 0.5-1 L/kg, reflecting limited extravascular distribution. |
| Bioavailability | Oral: 0% (degraded in gastrointestinal tract). Intravenous: 100%. |
| Onset of Action | Intravenous: within seconds to minutes for angiotensin II generation. Oral: not applicable (renin is a protein, degraded in GI tract). |
| Duration of Action | Intravenous: effects last 15-30 minutes due to rapid clearance. No depot formulations exist. |
10 mL intravenously over 1 hour three times per week on dialysis days.
| Dosage form | INJECTABLE |
| Renal impairment | No adjustment necessary; use only in patients on hemodialysis. |
| Liver impairment | No specific adjustments recommended; use caution in severe hepatic impairment. |
| Pediatric use | Safety and efficacy not established; no recommended dosing. |
| Geriatric use | Dose selection should be cautious, usually starting at the low end of the dosing range. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RENAMIN W/O ELECTROLYTES (RENAMIN W/O ELECTROLYTES).
| Breastfeeding | Unknown if excreted in human milk; caution advised; M/P ratio not established; consider benefits vs risks. |
| Teratogenic Risk | No teratogenic risk identified; Renamin (essential amino acid solution) is pregnancy category C; use only if clearly needed; no human data available; animal studies not conducted; theoretical risk of electrolyte imbalances affecting fetal development. |
| Fetal Monitoring |
■ FDA Black Box Warning
Not for use in patients with inborn errors of amino acid metabolism, severe liver disease, or metabolic acidosis. Risk of hyperammonemia, especially in pediatric patients.
| Serious Effects |
["Inborn errors of amino acid metabolism","Severe liver disease","Metabolic acidosis","Hypersensitivity to any component"]
| Precautions | ["Monitor for signs of hyperammonemia, azotemia, and electrolyte imbalances","Use with caution in renal impairment, hepatic disease, or acid-base disorders","Risk of infection from catheter use"] |
Loading safety data…
| Monitor maternal electrolytes, renal function, and fluid balance; fetal heart rate monitoring if maternal metabolic acidosis occurs. |
| Fertility Effects | No known effects on fertility; no human studies; theoretical hormonal disturbances from nutritional supplementation unlikely. |